scholarly journals A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects

2015 ◽  
Vol 79 (4) ◽  
pp. 650-659 ◽  
Author(s):  
Li Zheng ◽  
Mao Ping Li ◽  
Zhong Ping Gou ◽  
Ying Wang ◽  
Nan Xu ◽  
...  
Keyword(s):  
Healthy Subjects ◽  
Interferon Α ◽  
Consensus Interferon ◽  
Peginterferon Α

Expression and Aggregation of Recombinant Human Consensus Interferon-α Mutant by Pichia pastoris

2006 ◽  
Vol 28 (12) ◽  
pp. 905-909 ◽  
Author(s):  
Yuyou Hao ◽  
Ju Chu ◽  
Yonghong Wang ◽  
Siliang Zhang ◽  
Yingping Zhuang
Keyword(s):  
Pichia Pastoris ◽  
Interferon Α ◽  
Consensus Interferon

scholarly journals Tolerability and efficacy of pegylated consensus interferon-α in the treatment of chronic hepatitis C

2016 ◽  
Vol 13 (1) ◽  
pp. 9-16 ◽  
Author(s):  
Yan-Hua Ding ◽  
Bin Liu ◽  
Xin Zhang ◽  
Li Sun ◽  
Hong Zhang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Interferon Α ◽  
Consensus Interferon

scholarly journals Short-Term Probiotic Administration Increases Fecal-Anti Candida Activity in Healthy Subjects

2019 ◽  
Vol 7 (6) ◽  
pp. 162 ◽  
Author(s):  
Massimiliano De Angelis ◽  
Carolina Scagnolari ◽  
Alessandra Oliva ◽  
Eugenio Nelson Cavallari ◽  
Luigi Celani ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Healthy Subjects ◽  
Interferon Α ◽  
Probiotic Supplementation ◽  
Host Immune Responses ◽  
Vulnerable Patients ◽  
Healthy Donors ◽  
Before And After ◽  
Patients At Risk ◽  
The Relationship

Background: Candida albicans’ ability to evade host immune responses represents a serious threat for vulnerable patients. Objectives: To investigate if (1) feces from healthy subjects exert anti-Candida activity; (2) fecal anti-Candida activity is modified by probiotic administration and (3) different probiotic differently modulate anti-Candida activity. Patients and methods: Feces from healthy donors were analyzed before and after seven days of dietary supplementation with two different probiotic formulations (VSL#3®; Vivomixx®). Candida albicans was cultured with decreasing concentrations of diluted feces, obtained before and after the treatment period. The relationship between anti-Candida activity of feces, interferon-α, anti-interferon-α antibodies and the expression of MxA, ISG15 and IFNAR1 was also evaluated. Results: Feces obtained prior to probiotic intake and feces collected after supplementation with VSL#3® did not affect Candida albicans growth. On the contrary, a 3log10 inhibition of Candida development was observed after Vivomixx® intake. Interferon-α played a role in the inhibition of Candida growth. Conclusion: Fecal anti-Candida activity was not observed prior to probiotic supplementation. Seven days of administration of Vivomixx® increased fecal anti-Candida activity, the same effect was not observed after intake of VSL#3®. The probiotic-induced anti-Candida activity seems to be related to an increased local production and release of interferon-α. Clinical trials are needed to determine if a short pretreatment with specific probiotic formulations may increase anti-Candida defenses in patients at risk.

Interferon-α-2b/peginterferon-α-2b

2012 ◽  
Vol &NA; (1394) ◽  
pp. 26-27
Author(s):  
&NA;
Keyword(s):  
Interferon Α ◽  
Peginterferon Α

Structural characterization of recombinant consensus interferon-α

1988 ◽  
Vol 454 ◽  
pp. 205-215 ◽  
Author(s):  
Michael L. Klein ◽  
Timothy D. Bartley ◽  
Por-Hsiung Lai ◽  
Hsieng S. Lu
Keyword(s):  
Structural Characterization ◽  
Interferon Α ◽  
Consensus Interferon

Interferon-α-2a/peginterferon-α-2a

2010 ◽  
Vol &NA; (1288) ◽  
pp. 24
Author(s):  
&NA;
Keyword(s):  
Interferon Α ◽  
Peginterferon Α

Interferon-α-2b/peginterferon-α-2b

2012 ◽  
Vol &NA; (1409) ◽  
pp. 28
Author(s):  
&NA;
Keyword(s):  
Interferon Α ◽  
Peginterferon Α
Sign in / Sign up

Export Citation Format

Share Document